Desalegn G, Abrahamson C, Ross Turbyfill K, Pill-Pepe L, Bautista L, Tamilselvi C
NPJ Vaccines. 2025; 10(1):6.
PMID: 39805874
PMC: 11731012.
DOI: 10.1038/s41541-025-01064-6.
Scott T, Baker K, Trotter C, Jenkins C, Mostowy S, Hawkey J
Nat Rev Microbiol. 2024; .
PMID: 39604656
DOI: 10.1038/s41579-024-01126-x.
Boerth E, Gong J, Roffler B, Hancock Z, Berger L, Song B
Vaccines (Basel). 2024; 12(10).
PMID: 39460258
PMC: 11510904.
DOI: 10.3390/vaccines12101091.
Rossi O, Citiulo F, Giannelli C, Cappelletti E, Gasperini G, Mancini F
NPJ Vaccines. 2023; 8(1):130.
PMID: 37670042
PMC: 10480147.
DOI: 10.1038/s41541-023-00725-8.
Kelly M, Mandlik A, Charles R, Verma S, Calderwood S, Leung D
Vaccine. 2023; 41(34):4967-4977.
PMID: 37400283
PMC: 10529421.
DOI: 10.1016/j.vaccine.2023.06.052.
Development of the 2a, 3a, 6, and artificial Invaplex (Invaplex) vaccines.
Ross Turbyfill K, Clarkson K, Oaks E, Zurawski D, Vortherms A, Kaminski R
mSphere. 2023; 8(4):e0007323.
PMID: 37389412
PMC: 10449495.
DOI: 10.1128/msphere.00073-23.
Toward a Vaccine: Opportunities and Challenges to Fight an Antimicrobial-Resistant Pathogen.
Raso M, Arato V, Gasperini G, Micoli F
Int J Mol Sci. 2023; 24(5).
PMID: 36902092
PMC: 10003550.
DOI: 10.3390/ijms24054649.
Design of a Bacteriophage Cocktail Active against Species and Testing of Its Therapeutic Potential in .
Filippov A, Su W, Sergueev K, Kevorkian R, Snesrud E, Srijan A
Antibiotics (Basel). 2022; 11(11).
PMID: 36421303
PMC: 9686686.
DOI: 10.3390/antibiotics11111659.
Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data.
Cohen D, Ashkenazi S, Schneerson R, Farzam N, Bialik A, Meron-Sudai S
Clin Microbiol Infect. 2022; 29(3):366-371.
PMID: 36243351
PMC: 9993342.
DOI: 10.1016/j.cmi.2022.10.011.
The Vaccines Pipeline.
MacLennan C, Grow S, Ma L, Steele A
Vaccines (Basel). 2022; 10(9).
PMID: 36146457
PMC: 9504713.
DOI: 10.3390/vaccines10091376.
Setup and Characterization of a High-Throughput Luminescence-Based Serum Bactericidal Assay (L-SBA) to Determine Functionality of Human Sera against .
Mancini F, Micoli F, Rossi O
BioTech (Basel). 2022; 11(3).
PMID: 35997337
PMC: 9396978.
DOI: 10.3390/biotech11030029.
Detoxified O-Specific Polysaccharide (O-SP)-Protein Conjugates: Emerging Approach in the Vaccine Development Scene.
Cohen D, Meron-Sudai S, Bialik A, Asato V, Ashkenazi S
Vaccines (Basel). 2022; 10(5).
PMID: 35632431
PMC: 9145086.
DOI: 10.3390/vaccines10050675.
Shigella-Controlled Human Infection Models: Current and Future Perspectives.
Clarkson K, Porter C, Talaat K, Kapulu M, Chen W, Frenck Jr R
Curr Top Microbiol Immunol. 2022; 445:257-313.
PMID: 35616717
PMC: 7616482.
DOI: 10.1007/82_2021_248.
From Concept to Clinical Product: A Brief History of the Novel Invaplex Vaccine's Refinement and Evolution.
Ross Turbyfill K, Clarkson K, Oaks E, Kaminski R
Vaccines (Basel). 2022; 10(4).
PMID: 35455297
PMC: 9025769.
DOI: 10.3390/vaccines10040548.
Pivotal Vaccine Efficacy Trials-Study Design Considerations from a Vaccine Trial Design Working Group.
Pavlinac P, Rogawski McQuade E, Platts-Mills J, Kotloff K, Deal C, Giersing B
Vaccines (Basel). 2022; 10(4).
PMID: 35455238
PMC: 9032541.
DOI: 10.3390/vaccines10040489.
Towards a Four-Component GMMA-Based Vaccine against .
Micoli F, Nakakana U, Scorza F
Vaccines (Basel). 2022; 10(2).
PMID: 35214786
PMC: 8880054.
DOI: 10.3390/vaccines10020328.
Pathogenomic analyses of Shigella isolates inform factors limiting shigellosis prevention and control across LMICs.
Bengtsson R, Simpkin A, Pulford C, Low R, Rasko D, Rigden D
Nat Microbiol. 2022; 7(2):251-261.
PMID: 35102306
PMC: 8813619.
DOI: 10.1038/s41564-021-01054-z.
-Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either Shigella flexneri 2a or Shigella sonnei.
Clarkson K, Porter C, Talaat K, Frenck Jr R, Alaimo C, Martin P
mSphere. 2021; 6(4):e0012221.
PMID: 34259559
PMC: 8386581.
DOI: 10.1128/mSphere.00122-21.
A One Health Perspective for Defining and Deciphering Pathogenic Potential in Multiple Hosts.
Garcia A, Fox J
Comp Med. 2021; 71(1):3-45.
PMID: 33419487
PMC: 7898170.
DOI: 10.30802/AALAS-CM-20-000054.
Bacteria That Cause Enteric Diseases Stimulate Distinct Humoral Immune Responses.
Amadou Amani S, Lang M
Front Immunol. 2020; 11:565648.
PMID: 33042146
PMC: 7524877.
DOI: 10.3389/fimmu.2020.565648.